Two important types of COVID therapeutics are monoclonal antibodies and antivirals.
As of late 2022, the U.S. Food and Drug Administration (FDA) had authorized or approved the use of two monoclonal antibodies (Bebtelovimab and Evusheld) and three antiviral drugs (Veklury/Remdesivir, Paxlovid, and Lagevrio/molnupiravir).
However, the SARS-CoV-2 variants in circulation has raised concerns about the efficacy of these therapeutics, in particular the monoclonal antibodies. On November 30, 2022, the FDA withdrew the authorization for Bebtelovimab and on January 26, 2023, the FDA withdrew authorization for Evusheld.
As of January 27, 2022, Paxlovid, Veklury (remdesivir) and Lagevrio (molnupiravir) continue to remain authorized as COVID therapeutics.
The purpose of this question is to understand the likelihood of there no longer being any authorized monoclonal antibodies or antivirals in the U.S. in 2023.